Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib - Wikidata - wikimedia - TriplyDB

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib

http://www.wikidata.org/entity/Q34625305

about

Prognostic Value of Basic Fibroblast Growth Factor (bFGF) in Lung Cancer: A Systematic Review with Meta-Analysis MR Imaging Biomarkers in Oncology Clinical Trials Recent Advances in CT and MR Imaging for Evaluation of Hepatocellular Carcinoma Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis.Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience State of the art: Response assessment in lung cancer in the era of genomic medicine Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.Biomarkers in tumor angiogenesis and anti-angiogenic therapy.CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitiv Recent progress in protein profiling of clinical tissues for next-generation molecular diagnostics.Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.Comparison of CT volumetric measurement with RECIST response in patients with lung cancer.Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer.DCE-MRI Perfusion and Permeability Parameters as predictors of tumor response to CCRT in Patients with locally advanced NSCLC.Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.Sorafenib in non-small cell lung cancer.Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.Emerging protein kinase inhibitors for non-small cell lung cancer.Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?Multi-modal magnetic resonance imaging and histology of vascular function in xenografts using macromolecular contrast agent hyperbranched polyglycerol (HPG-GdF).Dynamic gadobutrol-enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model.Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?Evaluation of therapeutic effect of tumor-targeted therapy.KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.Implications of KRAS mutations in acquired resistance to treatment in NSCLC.Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy.[The targets research of non-small cell lung cancer targeted therapy].

P2860

Q26772984-52282F96-38A4-40BA-AE43-FECC1D7EAF0B Q30364608-3E2465DE-155D-4941-A80A-D70B7E9E6E63 Q30448049-ACED815F-7D30-4BBA-A832-EB840B2E93C6 Q33413742-987C246A-7F95-4F6C-8697-B997634860C5 Q33440392-BE0B24DB-3902-4FE7-8CD9-A5755DF3C00C Q33823191-6DF2BDBD-A798-446A-B506-4272205DC670 Q34337865-FAB52BC7-7636-4DB3-965F-E0EECDD6746D Q34681069-287B0A3F-16EE-417F-96EF-59C99A3DF585 Q35169154-D40D872A-532D-4106-A6E1-04C70F18A37B Q35536088-B8FD0163-3DD9-4BD4-A50E-F16CDE151A0A Q35669792-E7417B76-08CD-4122-8F04-2D287B9B8639 Q35714211-405C54F8-FEEC-4019-9B76-F3FC21B540EE Q36070099-AFB310BC-95C5-48C1-926E-B4959748CBFD Q36241287-0629A96B-2A5D-4904-8E3D-53051EA49EDF Q36270115-A83BDB1F-C015-47EA-9FB0-658255907C38 Q36369197-7AA6BBB4-C9A9-433B-80BA-DD13747261C3 Q36569753-F3DAFF6D-44E6-4B71-9C21-15396DA3C975 Q36864032-AAA7C888-31BA-404F-8040-B025FE45EADF Q37088411-6E5DA039-3497-49D3-A0AF-BE4DAD64160D Q37352786-054EEBB5-9BD3-458A-8DAB-94ED2A8BDF1C Q37526488-4DEEA536-A31F-4227-A1A8-18EED8D79FB3 Q37721529-FAA28DDA-A08C-40CF-89E9-34119090A95E Q37983692-712061EF-8367-45E5-B69E-BD381B1F3DFA Q38020917-4A74C495-93D1-4257-85CB-F5AF6D455C13 Q38103397-F1A71297-BDED-4714-B1A6-411F8C735DA7 Q38172608-525EECF7-EBAE-402A-A2A6-492D1758EC6A Q38672966-3CCF484C-9A52-4057-A4D9-990536B46CAB Q38844101-4031404A-920F-429A-A9B2-D0FC85C17144 Q39141313-2213DAE2-811B-4A1D-8364-CC43314DBF4D Q41867909-1EBE42C1-7CBA-441E-B4B1-F43A6E3EE5C4 Q41962463-98D17FE8-9A72-40E5-A942-E784990165E3 Q44658636-79B2EB46-324B-4958-B8EB-022DF213B403 Q48223594-05F069B8-269A-46B1-84D2-5EA925C0CC58 Q49787333-E9844427-3A71-44FF-B9E2-0850B97E55E0 Q54393339-2665DB72-6DD9-4549-83CF-DDC9670FAF6E Q55434033-941F7DA8-1E4B-464C-B896-9741B44887EF

P2860

Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib

http://www.wikidata.org/entity/Q34625305

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Evaluation of KRAS mutations, ...... ung cancer receiving sorafenib

@ast

Evaluation of KRAS mutations, ...... ung cancer receiving sorafenib

@en

Evaluation of KRAS mutations, ...... ung cancer receiving sorafenib

@nl

type

label

Evaluation of KRAS mutations, ...... ung cancer receiving sorafenib

@ast

Evaluation of KRAS mutations, ...... ung cancer receiving sorafenib

@en

Evaluation of KRAS mutations, ...... ung cancer receiving sorafenib

@nl

prefLabel

Evaluation of KRAS mutations, ...... ung cancer receiving sorafenib

@ast

Evaluation of KRAS mutations, ...... ung cancer receiving sorafenib

@en

Evaluation of KRAS mutations, ...... ung cancer receiving sorafenib

@nl

P1433

Q34625305-1E16B0FA-BB08-4B42-AD0E-4A3F532BAE5C

P1476

Q34625305-B02969CD-4A8E-40F7-9AFC-38F0E137F5C5

P2093

Q34625305-0BFF8006-6020-4C63-B0D9-7A5F3329DAAC

Q34625305-124DE70E-988E-44E8-B74C-E1DD6422D8C3

Q34625305-298475DE-F6B1-47DC-8F61-FC96300D1FD5

Q34625305-2FC37F15-79EE-47A6-A005-7A3531AB8ACE

Q34625305-2FE06C7B-F424-40DC-A2E9-3CC257772B06

Q34625305-3DA3D2DB-DDED-45A1-8943-52BEF1FF9A02

Q34625305-65B33737-D903-4FC6-8A3D-120BABA9ECFF

Q34625305-756245AC-80B0-4EDB-86D3-519A2FF1679F

Q34625305-8BC0D094-0C39-4A5E-9AF1-4895AB864A4A

Q34625305-8ECC0156-C615-4FD5-B45A-52D7B245EE3F

P2860

Q34625305-07FB1B8F-43AB-4B2C-A653-264B56392D48

Q34625305-0D4B9C52-D695-4092-A9FE-A14DFC9EFA7B

Q34625305-18F937FF-3546-4B7B-8A65-56260FB6BD1D

Q34625305-21007F46-C670-41BA-A869-5572DD9B28CE

Q34625305-2510FF8A-6CE3-44FF-9D46-B9741ADE679F

Q34625305-3233DD3C-B766-45D6-B45C-4C857C4F873E

Q34625305-3505F38B-5D20-44C5-B62B-909FE0A777D7

Q34625305-367B1365-DB8B-4225-88D1-73934D09FE26

Q34625305-46558340-C000-4020-BE42-C617F8CEC172

Q34625305-47742B74-7E77-4616-9B89-C8DC17003207

P304

Q34625305-3AD0EEF8-0E6A-4C29-B48B-324ECFBC009B

P31

Q34625305-615F2FE2-36D4-4262-9176-A710B7C28798

P356

Q34625305-CB66BA3F-B4F8-4F50-9205-FCCF86CFF580

P407

Q34625305-F89F1DAE-E45F-4C83-A41E-230E7EE48472

P433

Q34625305-8A5A4254-BB34-46F5-AC69-4AEAE782C947

P478

Q34625305-992C905A-DD99-454F-A418-A6BA02FAA87C

P577

Q34625305-185EED8E-90D7-459D-84CF-BFC8ACB0A03F

P5875

Q34625305-DB069367-DF34-4F33-ACAD-3071BDE266C0

P698

Q34625305-F9A2DD0E-DA17-4FDB-8CAA-30D5C14EF152

P921

Q34625305-1ED1DEFF-7CF1-4D7D-987C-6657D6B2994E

P932

Q34625305-2961309B-A398-4C68-8182-19367C7B2175

P356

1078-0432.CCR-10-2331

P1433

Clinical Cancer Research

P1476

Evaluation of KRAS mutations, ...... ung cancer receiving sorafenib

@en

P2093

Ariel Lopez-Chavez

http://www.w3.org/2001/XMLSchema#string

Arun Rajan

http://www.w3.org/2001/XMLSchema#string

Baris Turkbey

http://www.w3.org/2001/XMLSchema#string

Corrine Keen

http://www.w3.org/2001/XMLSchema#string

Giuseppe Giaccone

http://www.w3.org/2001/XMLSchema#string

Jeremy Force

http://www.w3.org/2001/XMLSchema#string

John J Wright

http://www.w3.org/2001/XMLSchema#string

Liang Cao

http://www.w3.org/2001/XMLSchema#string

Liqiang Xi

http://www.w3.org/2001/XMLSchema#string

Mark Raffeld

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Erlotinib in previously treated non-small-cell lung cancer

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Screening for epidermal growth factor receptor mutations in lung cancer

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

BAY 43-9006: preclinical data.

Dynamic contrast-enhanced magnetic resonance imaging in oncology.

P304

1190-1199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-2331

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49745215

http://www.w3.org/2001/XMLSchema#string

P698

21224376

http://www.w3.org/2001/XMLSchema#string

P921

P932

3048919

http://www.w3.org/2001/XMLSchema#string